All Relations between Depression and Psilocybin

Publication Sentence Publish Date Extraction Date Species
Noah Chisamore, Danica Johnson, Margery J Q Chen, Hilary Offman, David Chen-Li, Erica S Kaczmarek, Zoe Doyle, Roger S McIntyre, Joshua D Rosenbla. Protocols and practices in psilocybin assisted psychotherapy for depression: A systematic review. Journal of psychiatric research. vol 176. 2024-06-08. PMID:38850581. protocols and practices in psilocybin assisted psychotherapy for depression: a systematic review. 2024-06-08 2024-06-11 Not clear
Mengyang Xu, Andor J Kiss, J Andrew Jones, Matthew S McMurray, Haifei Sh. Effect of oral tryptamines on the gut microbiome of rats-a preliminary study. PeerJ. vol 12. 2024-06-07. PMID:38846751. psilocybin and related tryptamines have come into the spotlight in recent years as potential therapeutics for depression. 2024-06-07 2024-06-10 Not clear
Laura Ramos, Selene G Vicent. The effects of psilocybin on cognition and emotional processing in healthy adults and adults with depression: a systematic literature review. Journal of clinical and experimental neuropsychology. 2024-06-06. PMID:38842300. the effects of psilocybin on cognition and emotional processing in healthy adults and adults with depression: a systematic literature review. 2024-06-06 2024-06-08 Not clear
Laura Ramos, Selene G Vicent. The effects of psilocybin on cognition and emotional processing in healthy adults and adults with depression: a systematic literature review. Journal of clinical and experimental neuropsychology. 2024-06-06. PMID:38842300. studying psilocybin effects on cognition and emotional processing may help to clarify the mechanisms underlying the therapeutic potential of psilocybin and may also support studies with people suffering from depression. 2024-06-06 2024-06-08 Not clear
Qiwen Fang, Vivien Kin Yi Chan, Sandra Sau Man Chan, Yuanshi Jiao, Jiaqi Wang, Xue L. Efficacy and safety of psilocybin on treatment-resistant depression: A systematic review and meta-analysis. Psychiatry research. vol 337. 2024-05-23. PMID:38781672. efficacy and safety of psilocybin on treatment-resistant depression: a systematic review and meta-analysis. 2024-05-23 2024-05-27 Not clear
David Nutt, Ilana Crome, Allan H Youn. Is it now time to prepare psychiatry for a psychedelic future? The British journal of psychiatry : the journal of mental science. 2024-05-19. PMID:38764044. australia has just rescheduled two drugs controlled under the united nations psychotropic drug conventions, psilocybin and mdma, as treatments for treatment-resistant depression and post-traumatic stress disorder respectively. 2024-05-19 2024-05-27 Not clear
Val Bellma. Review of Psilocybin Use for Depression among Cancer Patients after Approval in Oregon. Cancers. vol 16. issue 9. 2024-05-13. PMID:38730654. review of psilocybin use for depression among cancer patients after approval in oregon. 2024-05-13 2024-05-27 Not clear
Val Bellma. Review of Psilocybin Use for Depression among Cancer Patients after Approval in Oregon. Cancers. vol 16. issue 9. 2024-05-13. PMID:38730654. despite the legalization of psilocybin therapy for depression in terminal illnesses such as advanced cancer through oregon's measure 109 in 2020, significant challenges have impeded its implementation. 2024-05-13 2024-05-27 Not clear
EXPRESSION OF CONCERN: Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis. BMJ (Clinical research ed.). vol 385. 2024-05-04. PMID:38704154. expression of concern: efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis. 2024-05-04 2024-05-07 Not clear
Claire Parker, Bethany Marie Woo. At the Forefront: Social Workers' Role in Psilocybin Treatment for Depression and Substance Misuse. Social work. 2024-05-02. PMID:38697188. at the forefront: social workers' role in psilocybin treatment for depression and substance misuse. 2024-05-02 2024-05-05 Not clear
Riccardo De Giorgi, Roger Ed. Psilocybin for depression. BMJ (Clinical research ed.). vol 385. 2024-05-01. PMID:38692675. psilocybin for depression. 2024-05-01 2024-05-04 Not clear
Athina-Marina Metaxa, Mike Clark. Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis. BMJ (Clinical research ed.). vol 385. 2024-05-01. PMID:38692686. efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis. 2024-05-01 2024-05-04 Not clear
K Conn, L K Milton, K Huang, H Munguba, J Ruuska, M B Lemus, E Greaves, J Homman-Ludiye, B J Oldfield, C J Fold. Psilocybin restrains activity-based anorexia in female rats by enhancing cognitive flexibility: contributions from 5-HT1A and 5-HT2A receptor mechanisms. Molecular psychiatry. 2024-04-27. PMID:38678087. psilocybin has shown promise for alleviating symptoms of depression and is currently in clinical trials for the treatment of anorexia nervosa (an), a condition that is characterised by persistent cognitive inflexibility. 2024-04-27 2024-04-30 rat
Ram Harari, Ipsita Chatterjee, Dmitriy Getselter, Evan Elliot. Psilocybin induces acute anxiety and changes in amygdalar phosphopeptides independently from the 5-HT2A receptor. iScience. vol 27. issue 5. 2024-04-26. PMID:38660396. psilocybin has been proposed as a treatment for depression and anxiety but sometimes induces anxiety in humans. 2024-04-26 2024-04-28 mouse
Gail A Edelsohn, Dominic Sist. Past Is Prologue: Ethical Issues in Pediatric Psychedelics Research and Treatment. Perspectives in biology and medicine. vol 66. issue 1. 2024-04-25. PMID:38662012. mdma and psilocybin administered with psychotherapy have received fda designation as "breakthrough therapies" for post-traumatic stress disorder (ptsd) and treatment-resistant depression (trd) respectively. 2024-04-25 2024-04-28 Not clear
Jordan Sloshower, Richard J Zeifman, Jeffrey Guss, Robert Krause, Hamideh Safi-Aghdam, Surbhi Pathania, Brian Pittman, Deepak Cyril D'Souz. Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial. Scientific reports. vol 14. issue 1. 2024-04-17. PMID:38632313. additionally, improvements in psychological flexibility and experiential acceptance were strongly associated with reductions in depression severity following psilocybin. 2024-04-17 2024-04-20 Not clear
Sheng-Min Wang, Sunghwan Kim, Won-Seok Choi, Hyun Kook Lim, Young Sup Woo, Chi-Un Pae, Won-Myong Bah. Current Understanding on Psilocybin for Major Depressive Disorder: A Review Focusing on Clinical Trials. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 22. issue 2. 2024-04-16. PMID:38627070. fda designated psilocybin as a "breakthrough therapy" for the treatment of treatment-resistant depression (trd) in 2018. 2024-04-16 2024-04-19 Not clear
Sheng-Min Wang, Sunghwan Kim, Won-Seok Choi, Hyun Kook Lim, Young Sup Woo, Chi-Un Pae, Won-Myong Bah. Current Understanding on Psilocybin for Major Depressive Disorder: A Review Focusing on Clinical Trials. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 22. issue 2. 2024-04-16. PMID:38627070. this paper provided a review of psilocybin's potential role in treatment of depression by focusing on published clinical trials. 2024-04-16 2024-04-19 Not clear
Akhila Yerubandi, Jennifer E Thomas, N M Mahmudul Alam Bhuiya, Catherine Harrington, Lorenzo Villa Zapata, Joshua Caballer. Acute Adverse Effects of Therapeutic Doses of Psilocybin: A Systematic Review and Meta-Analysis. JAMA network open. vol 7. issue 4. 2024-04-10. PMID:38598236. psilocybin has been studied in the treatment of depression and anxiety disorders. 2024-04-10 2024-04-12 Not clear
Zarah R Haniff, Mariia Bocharova, Tim Mantingh, James J Rucker, Latha Velayudhan, David M Taylor, Allan H Young, Dag Aarsland, Anthony C Vernon, Sandrine Thure. Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases. Pharmacology & therapeutics. 2024-04-07. PMID:38583670. the potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases. 2024-04-07 2024-04-10 Not clear